Dr Charalampos Fragkoulis speaks to ecancer about a phase II trial by the Hellenic GU Cancer Group.

This trial investigates the intravesical administration of durvalumab to patients with high risk non muscle invasive bladder cancer after BCG failure. The trial was based on the hypothesis that intravesical administration of durvalumab will not be related with severe adverse events.

Dr Fragkoulis says that the study found that intravesical IO using durvalumab is feasible with an excellent safety profile. The trial has paved the way for further study of intravesical IO in high-risk patients with NMIBC after BCG failure.